Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 10, 2018
Distillery Techniques

Disease models

BioCentury | Aug 17, 2018
Targets & Mechanisms

Unsaturated remyelination

Case Western spins out Convelo to develop remyelination drugs
BioCentury | Dec 5, 2017
Distillery Therapeutics

Autoimmune disease

BioCentury | Aug 15, 2013
Distillery Techniques

Technology: Disease models

BioCentury | Oct 25, 2012
Distillery Therapeutics

Indication: Neurology

BioCentury | Oct 25, 2012
Targets & Mechanisms

Myelination from neural stem cells

BioCentury | Oct 8, 2012
Product Development

Opexa's progression in MS

Efficacy, MOA behind Opexa's shift to secondary progressive MS for Tcelna
BioCentury | Oct 7, 2010
Distillery Therapeutics

Indication: Autoimmune disease

Items per page:
1 - 9 of 9